BusinessNews.ph

Category: Medical

  • AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States

    Industry recognition for the third consecutive year reinforces AGFA HealthCare’s clinician-first commitment, and leadership in empowering connected, high-performance imaging environments

    AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company’s continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide.

    The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights.

    AGFA HealthCare’s Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform – designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinical decision-making through connected, high-performing access to images and data.

    Best in KLAS® – Enterprise Imaging (United States)

    • Enterprise Imaging for Radiology: ranked #1 with a 93.2% score in the PACS (Small – under 300k studies) segment.
    • XERO® Viewer: ranked #1 with a 92.1% score in the Universal Viewer (Imaging) segment for the third consecutive year
    • Enterprise Imaging VNA: ranked #1 with a 89.8% score in the Vendor Neutral Archive (VNA) segment for the second consecutive year.

    “Being recognized across three Enterprise Imaging segments – including multiple consecutive wins – is a powerful affirmation of our clinician-first strategy,” said Nathalie McCaughley, President of AGFA HealthCare. “Healthcare organizations trust us to deliver imaging environments that truly support clinicians in their daily work, while enabling IT and clinical leaders to operate with confidence, performance, and long-term vision. This recognition reflects the strength of our partnerships and our unwavering focus on empowering care teams through connected, intelligent imaging.”

    Commenting on the awards, Adam Gale, CEO of KLAS Research, said:

    “The Best in KLAS winners have earned the trust of their customers over the past year. With this recognition, they set the standard for excellence through partnership in healthcare technology and services in the months to come.”

    Monique Rasband, Global Vice President of Imaging at KLAS Research, added:
    “AGFA HealthCare’s strong performance across multiple Enterprise Imaging segments reflects consistent customer feedback. Organizations recognize the value of solutions that help imaging teams work efficiently today while providing a clear path for future growth and innovation.”

    The Best in KLAS awards are based on direct feedback from healthcare providers and recognize vendors who consistently demonstrate excellence through partnership, performance, and responsiveness to customer needs.

    AGFA HealthCare will celebrate its Best in KLAS recognition during HIMSS 2026, alongside customers and partners, as part of its continued commitment to advancing connected, intelligent, and human-centered imaging at scale.

    KLAS references

    About AGFA HealthCare
    At AGFA HealthCare, we understand that striking the critical balance between clinical efficiency and quality patient care starts with the clinician experience. We recognize how vital it is for clinicians to be fully immersed in their cases, channeling all their energy into delivering confident, informed diagnoses. That’s why we designed our Enterprise Imaging platform to eliminate the barriers that get in the way. When distractions melt away, technology feels like an extension of one’s thought process, and each clinician has everything they need to perform at the top of their craft. That’s life in flow.

    This belief shapes everything we do – guided by our Mission, Vision, and Customer Delivery Principles, which are designed to empower clinicians and elevate their experience.

    AGFA HealthCare is a division of the Agfa-Gevaert Group. For more information on AGFA HealthCare, please visit www.agfahealthcare.comand follow us on LinkedIn.

    AGFA and the Agfa rhombus are registered trademarks of Agfa-Gevaert N.V. Belgium or its affiliates. XERO is a registered trademark of Agfa HealthCare N.V. Belgium or its affiliates. All information contained herein is intended for guidance purposes only, and the characteristics of the products and services described in this publication can be changed at any time without notice. Products and services may not be available for your local area. Please contact your local sales representative for availability information. AGFA HealthCare diligently strives to provide as accurate information as possible but shall not be responsible for any typographical error.

    About KLAS Research
    KLAS Research is a leading healthcare IT data and insights company dedicated to improving global healthcare delivery by amplifying the voice of healthcare providers. Celebrating its 30th anniversary in 2026, KLAS evaluates vendor performance through independent research based on direct customer feedback.

    Best in KLAS® is a registered trademark of KLAS Research.

    Press Contact: Jessica Baldry, Global Marketing & Communications Manager, AGFA HealthCare +44 1206 413052 jessica.baldry@agfa.com

    SOURCE: Agfa HealthCare

     

  • Formerra and Evonik Expand Distribution Partnership for Healthcare Grades

    Agreement Expands Access to Evonik’s CARE Brand Medical Grades in the U.S. and Canada

    Formerra, a leader in performance materials distribution, today announced an expanded distribution agreement that brings Evonik’s CARE brand healthcare grades into Formerra’s medical portfolio. Covering the United States and Canada, the agreement creates new access points for high-performance polyamides used in essential healthcare applications.

    This expansion kicks off at MD&M West 2026 this week, and underscores both companies’ commitment to supporting the healthcare market with high-performance materials, responsive service, and continuity of supply. It also builds on the companies’ two-year partnership, which introduced Evonik’s VESTAMID® and TROGAMID® families to Formerra’s engineered materials lineup.

    With this expansion, Formerra will support Evonik healthcare grades designed for fluid handling, drug delivery, diagnostic systems, surgical instrument parts, medical device housings, components that see short-term body contact (< 30 days), and other non-implantable applications requiring strength, clarity, chemical resistance, and consistent processing.

    Key medical grade materials include:

    • VESTAMID® Care ML PA12
    • VESTAMID® Care ME PEBA elastomer
    • TROGAMID® Care MX microcrystalline PA

    “Our healthcare customers rely on stable supply, world-class regulatory support, and materials that perform under demanding conditions,” said Steve Harmon, Director, Key Accounts, Formerra. “Evonik’s healthcare grades bring the combination of durability, processing consistency, and documentation support that medical manufacturers require. This expansion lets us strengthen the technical resources and materials pipeline available to teams developing next-generation devices.”

    “Formerra’s ability to serve the whole supply chain in the medical space, from design companies to compounders to medical device OEMs, with technical rigor and exceptional logistics and with already-proven successful demonstration in the industrial space, made this expansion with CARE brand Polyamide 12 products a natural step,” said Basker Lalgudi, Business Manager, Global Medical Devices, Evonik. “Their healthcare expertise and focus help customers select and implement our materials with confidence across a range of critical applications.”

    By adding Evonik’s healthcare CARE brand materials, Formerra will offer customers a proven set of polyamide solutions that support regulatory pathways, design requirements, and long-term reliability. Formerra’s team will provide material selection guidance, processing support, and regional supply chain readiness to help OEMs and molders accelerate development cycles.

    Formerra will exhibit at MD&M West in Booth 2266 in Anaheim, California, Feb. 3-5, 2026.

    Key Details:

    • Formerra will distribute Evonik’s CARE brand healthcare grades across the U.S. and Canada.
    • Materials include healthcare grades within the VESTAMID® L, VESTAMID® E, and TROGAMID® CX families, plus designated sustainable options.
    • The agreement strengthens Formerra’s medical portfolio and expands its support for fluid management, diagnostics, wearables, and device housings.
    • Formerra will provide application guidance, regulatory documentation support, and supply chain continuity for medical customers.

    About Formerra
    Formerra is a preeminent distributor of engineered materials, connecting the world’s leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways, driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com.

    About Evonik
    Evonik goes beyond the boundaries of chemistry with its combination of innovative strength and leading technological expertise. The global chemical company, headquartered in Essen, Germany, is active in more than 100 countries and generated sales of €15.2 billion and earnings (adjusted EBITDA) of €2.1 billion in 2024. The common motivation of the approximately 32,000 employees: to provide customers with a decisive competitive advantage with tailor-made products and solutions as a superforce for industry, thereby improving people’s lives. In all markets. Every day. To learn more, visit www.evonik.com.

    Media Contact
    Jackie Morris
    Marketing Communications Manager, Formerra
    jackie.morris@formerra.com
    +1 630-972-3144

    SOURCE: Formerra

  • Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics

    Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics

    Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage biotechnology company developing platform technologies spanning glycovirology, hypoxia, and degenerative diseases, announced the execution of a Sponsored Research Agreement with the University of Minnesota to support advanced biochemical research aimed at improving the understanding and development of novel polysaccharide and oligosaccharide interactions with biologically relevant targets.

    Under the agreement, research will be conducted at the University of Minnesota under the direction of Dr. Kevin Mayo, a recognized expert in biomolecular structure and nuclear magnetic resonance spectroscopy The collaboration is designed to further characterize carbohydrate-binding interactions that may play a role in future therapeutic and diagnostic applications.

    “This collaboration with the University of Minnesota represents an important step in strengthening the scientific foundation behind our carbohydrate-based technology platform,” said David Platt, CEO of Bioxytran. “By leveraging the University’s deep expertise in structural biology and advanced nuclear magnetic resonance spectroscopy, we aim to generate high-quality data that supports the continued evolution of our research and development pipeline.”

    Research Focus

    The sponsored research program will explore how specific polysaccharides and related carbohydrate structures interact with target molecules relevant to biological systems. Using state-of-the-art nuclear magnetic resonance  methodologies, the research team will analyze binding interactions, structural conformations, and affinity characteristics of select carbohydrate compounds. The work is expected to build on Bioxytran’s existing research into carbohydrate-based materials and their potential applications across biomedical and life-science domains. Findings from the study may help guide future development strategies and inform additional preclinical research initiatives.

    Academic–Industry Collaboration

    The agreement reflects a shared commitment to advancing scientific knowledge through collaboration between academia and industry. The University of Minnesota will carry out the research in accordance with its established academic standards, ensuring scientific rigor, transparency, and adherence to institutional research policies.

    This type of partnership exemplifies how academic research institutions and innovative companies can work together to address complex scientific questions,” said Dr. Kevin Mayo, Principal Investigator and Professor at the University of Minnesota. “Our goal is to apply advanced analytical tools to generate insights that are both scientifically meaningful and relevant to real-world applications.”

    Timeline and Structure

    The research term is expected to run through early 2027, with defined milestones, periodic progress reviews, and structured reporting. Bioxytran will provide funding to support research personnel, nuclear magnetic resonance facility access, and associated laboratory resources required to execute the program. In accordance with standard sponsored research practices, the University of Minnesota will retain ownership of any intellectual property generated through the research, while Bioxytran will receive broad rights to use the resulting research data for internal research and development purposes.

    Strategic Significance

    For Bioxytran, the collaboration supports a broader strategy focused on strengthening its scientific validation, expanding academic partnerships, and advancing next-generation carbohydrate technologies. The company believes that well-characterized molecular interactions are a critical step toward unlocking new therapeutic pathways and accelerating innovation.The University of Minnesota continues to be recognized globally for its leadership in biomedical research and technology transfer, making it an ideal partner for companies seeking to bridge fundamental science and commercial development.

    About the University of Minnesota

    The University of Minnesota is one of the nation’s leading public research universities, known for its commitment to discovery, innovation, and the translation of research into real-world impact. Through industry partnerships and sponsored research programs, the University fosters collaboration that advances science and benefits society.

    About Bioxytran, Inc.

    Bioxytran is a clinical-stage pharmaceutical company developing platform technologies in glycovirology, hypoxia and degenerative diseases using carbohydrate drug design, including programs that leverage galectin inhibition and programs that aim to address hypoxic conditions and tissue oxygenation.

    Bioxytran’s common stock trades on the OTCQB under the symbol BIXT.

    Company Contact:
    Bioxytran, Inc.
    75 Second Avenue, Needham, MA 02494
    Phone: 617‑454‑1199
    Email: info@Bioxytraninc.com
    Web: www.Bioxytraninc.com

    Forward-Looking Statements

    This press release contains forward-looking statements, including statements regarding anticipated regulatory interactions, future clinical trials, trial designs, timing of data submission and publication, and potential therapeutic and commercial opportunities. Forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Readers are urged to review the Company’s risk factors disclosed in its reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10‑K for the year ended December 31, 2024.

  • Formerra to Supply Foster Medical Compounds in Europe

    Expanded agreement infuses Formerra’s European healthcare polymer portfolio with life-saving Foster compounds.

    PUTNAM, CT AND ROMEOVILLE, IL, Jan 29, 2026 – (ACN Newswire) – Formerra and GEON® Performance Solutions today announced an agreement that designates Formerra as the preferred distributor of Foster®, LLC medical compounds in Europe. This adds to Formerra’s current distribution of these materials in North and South America, enabling Formerra to now support customers who need the same product in all regions.

    Following GEON’s January 2025 acquisition of Foster, the agreement builds on Formerra’s long-standing, global partnership with GEON for flexible and rigid PVC and filled polypropylene materials.

    “Bringing Foster’s medical-grade portfolio to Europe strengthens our ability to support healthcare manufacturers across the region with specialized compounds and the local expertise they need to navigate complex regulatory environments,” said Kelly Wessner, Vice President, Key Accounts, Formerra. “Building on the momentum of our Americas partnership, we’re excited to extend these proven solutions to European customers who demand the highest standards in medical device materials.”

    With more than 30 years in custom medical polymer compounding, Foster delivers highly engineered, top-of-the-polymer-pyramid formulations tailored to demanding requirements. The portfolio includes options such as radiopaque compounds and grades that meet USP Class VI requirements and align with ISO 10993 expectations. These materials support critical end uses across the healthcare space, including implantable products and other highly specialized applications.

    “Extending our Foster portfolio into Europe with Formerra allows us to meet growing demand from healthcare manufacturers in one of the world’s most dynamic medical device markets,” said Arthur Adams, Chief Commercial Officer, GEON. “This expansion reinforces our shared commitment to supporting innovation in life-saving applications globally.”

    Adding Foster® compounds to its European portfolio will enable Formerra to better serve customers in the healthcare space, offering not only access to highly engineered medical polymers, but also deep regulatory expertise and responsive logistics across the region.

    Formerra will exhibit at MD&M West in Booth 2266 in Anaheim, California, February 3-5, 2026.

    Key Details

    • Formerra will distribute Foster® medical compounds in Europe.
    • This agreement adds custom medical-grade compounds to Formerra’s existing global access to GEON® PVC and filled PP materials.

    About Formerra

    Formerra is a preeminent distributor of engineered materials, connecting the world’s leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways – driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com.

    Media Contact
    Jackie Morris
    Marketing Communications Manager, Formerra
    jackie.morris@formerra.com
    +1 630-972-3144

    SOURCE: Formerra

  • Bioxytran Provides Corporate Update Highlighting Momentum Across Its Multi-Platform Pipeline

    Bioxytran Provides Corporate Update Highlighting Momentum Across Its Multi-Platform Pipeline

    Company reiterates focus on advancing ProLectin-M under an active FDA IND and progressing oxygen-transport programs for stroke and neurodegenerative disease

    Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage biotechnology company developing platform technologies spanning glycovirology, hypoxia, and degenerative diseases, today issued a corporate update summarizing previously disclosed program developments and reinforcing the Company’s strategic direction entering 2026. (BioXyTran)

    Corporate Update Highlights (Previously Disclosed)

    ProLectin‑M (broad-spectrum antiviral platform)

    Bioxytran’s lead antiviral program, ProLectin‑M, is being developed under an active U.S. FDA Investigational New Drug (IND) framework, as previously announced by the Company.

    In October 2025, the Company announced the completion of a randomized, double-blind, placebo-controlled clinical trial for ProLectin‑M and stated that data from the trial is expected to help inform Phase 3 trial design and be submitted to regulators pursuant to prior regulatory interactions. (BioXyTran)

    In May 2025, Bioxytran also announced completion of dose optimization work intended to support additional clinical trial planning and agency submissions.

    Oxygen transport platform (stroke and neurodegenerative diseases)

    Bioxytran continues to advance its oxygen-transport platform, including development efforts related to a universal oxygen carrier (UOC) and associated measurement/analytical approaches previously described by the Company, including use of the MDX Viewer, which the Company has described as an FDA-approved device to measure tissue oxygenation.

    In July 2024, Bioxytran announced a joint venture with the Heme Foundation to develop a universal oxygen carrier as an alternative to blood transfusions, including public statements regarding a pledged level of support and reported development progress at that time.

    Oncology research (Galectin Science)

    In January 2025, the Company announced a cancer-focused preprint exploring galectin‑3 modulation as a potential strategy to improve response to immune checkpoint inhibitors. (Nasdaq)

    Management Commentary

    “Bioxytran enters 2026 with real momentum across our platforms,” said David Platt, Ph.D., Chief Executive Officer of Bioxytran. “Across virology and oxygen transport, our team has stayed focused on disciplined execution—building the data package, advancing the regulatory pathway, and expanding the scientific foundation that supports our programs. We believe our carbohydrate-based approach and galectin science position Bioxytran to pursue meaningful clinical and strategic opportunities as we continue to move forward.”

    Disclosure Note

    This release is intended as a general corporate update and summarizes information that has been previously disclosed in Company press releases and public filings.

    About Bioxytran, Inc.

    Bioxytran is a clinical-stage pharmaceutical company developing platform technologies in glycovirology, hypoxia and degenerative diseases using carbohydrate drug design, including programs that leverage galectin inhibition and programs that aim to address hypoxic conditions and tissue oxygenation.

    Bioxytran’s common stock trades on the OTCQB under the symbol BIXT.

    Company Contact:
    Bioxytran, Inc.
    75 Second Avenue, Ste 605, Needham, MA 02494
    Phone: 617‑454‑1199
    Email: info@bioxytraninc.com
    Web: www.bioxytraninc.com

    Forward-Looking Statements

    This press release contains forward-looking statements, including statements regarding anticipated regulatory interactions, future clinical trials, trial designs, timing of data submission and publication, and potential therapeutic and commercial opportunities. Forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Readers are urged to review the Company’s risk factors disclosed in its reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10‑K for the year ended December 31, 2024.

  • Geon Performance Solutions Updates Brand Identity to Reflect Expanded Capabilities in Polymer Industry

    Geon® Performance Solutions, a global leader in high-value polymer solutions, announces a comprehensive brand refresh. The update reflects the company’s strategy to enhance and diversify its portfolio of engineered polymer solutions and advance its role as a solutions-driven partner.

    Propelled by the need for sustainable materials, advanced technology, and circular economy goals, the polymer industry is transforming. Geon’s refreshed brand identity demonstrates its commitment to leading in this evolving market and collaborating with customers to outthink constraints and build inspired solutions.

    “Geon has a century of proven performance and one of the industry’s most extensive polymer formulation libraries. Our refreshed brand better captures the innovation, agility and ambition of our enterprise,” said Tracy Garrison, Geon’s chief executive officer. “The brand refresh matches the momentum and determination of our people, while holding true to the company’s heritage and highlighting the human touch Geon brings to its customers.”

    The brand refresh represents an important milestone in Geon’s growth, aligning its visual identity with the demands of its customers and the polymer marketplace – especially following the Company’s acquisition of Foster Corporation, a world leading compounder of biomedical polymers used in the healthcare and medical device industry. The acquisition was Geon’s fourth in a span of five years – a key component of its strategy to diversify its portfolio of engineered polymer solutions.

    “While our look is changing, Geon’s solutions offerings continue to open endless possibilities to help customers build smart solutions for a better tomorrow,” said Garrison. “We are innovating across our value chain and exploring new partnerships for smart polymer solutions in markets such as medical and power and communication.”

    The refreshed brand will be rolled out across all channels in January 2026.

    About Geon Performance Solutions
    Geon® Performance Solutions unlocks the power of polymers for the future. From biomedical materials from our medical division, Foster, LLC, to building materials, automotive, connectivity, and appliances, customers in these markets rely on the portfolio of compounding solutions, highly adaptable vinyl, polyolefin, engineered resin technologies, and full-service contract manufacturing that we deliver. In every formulation, collaboration, and challenge, we’re shaping the brilliance of tomorrow and providing a formidable advantage by engineering what’s possible. Geon has approximately 1,200 global associates and 15 world-class manufacturing plants with headquarters in Westlake, Ohio. Learn more at www.geon.com. Geon is a portfolio company of SK Capital Partners.

    About SK Capital Partners
    SK Capital is a transformational private investment firm with a disciplined focus on the life sciences, specialty materials, and ingredients sectors. The firm seeks to build resilient, sustainable, and growing businesses that create substantial long-term value. SK Capital aims to utilize its industry, operating, and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth, and profitability, as well as lower operating risk. SK Capital currently has approximately $10 billion in assets under management as of December 31, 2025. For more information, please visit www.skcapitalpartners.com.

    Media Contact
    Jen Martin, Marketing Director
    Jennifer.Martin@geon.com
    +1-440-249-1508

    SOURCE: Geon Performance Solutions

  • A True Empowerer – AGFA HealthCare Radiates Imaging Innovation at ECR 2026

    In Vienna, Enterprise Imaging offers the “Clinician-First” approach to keeping radiologists in their flow, spotlighting the human behind the innovation and empowering them to work in comfort with their technology.

    At ECR 2026, AGFA HealthCare will unveil its latest imaging innovations that transform the clinician experience and drive smarter care. Turning knowledge into action, AGFA delivers advancements which empower radiologists with seamless workflows, intelligent automation and tailored diagnostic environments. Under the event 2026 theme “Rays of Knowledge”, AGFA is ready to demonstrate how we have reached the summit of Empowerer – adopting the ‘Clinician-First’ approach, which demonstrates a profound understanding of the clinician’s challenges and workflow realities.

    “Clinician First is more than a message – it’s a mindset”, says Andrea Polticchia, Regional President for Southern Europe, AGFA HealthCare. “This approach reflects our deepened commitment – technology exists to serve clinicians, not the other way around. We are seen as the Empowerer in our markets – a partner that understands, anticipates, and designs for the clinician real world experience. This is the level of empowerment that truly supports clinicians – and when clinicians are supported, patient care thrives.”

    Built for the people, not just the image, AGFA HealthCare’s Enterprise Imaging platform is designed to keep clinicians, IT teams and healthcare enterprises focused, confident and in control. More than a solution, it’s a connected ecosystem that unifies teams and technologies, simplifies complexity and strengthens collaboration across the care continuum. It’s where advanced technology meets real human need, turning complexity into clarity and burnout into balance.

    “ECR has long stood as the pinnacle of European radiological excellence and is the perfect stage to empower the clinical community,” says Roberto Anello, Regional President for Northern Europe, AGFA HealthCare. “Enterprise Imaging brings precision and clarity to every clinical moment, transforming years of experience into seamless diagnostic flow. AGFA HealthCare, has reached a new summit, where deep clinical insight, cutting-edge technology, and human connection converge. Every click, every case, every collaboration is purpose-built around the radiologist’s reality, whether at the hospital, at home, or across a connected care network.”

    What’s New at ECR 2026:
    Streaming Client – Blazing fast. Wherever you are.

    With AGFA HealthCare’s zero-footprint Streaming Client, radiologists enjoy a full diagnostic experience right in their browser. Combining blazing speed with full-fidelity and personalized workflow tools, it allows them to read from any location with the same precision and familiarity they expect on-site.

    RUBEE® Orchestrator – The right case to the right radiologist at the right time

    Workflow Orchestration, powered by RUBEE®, helps radiology teams stay aligned, efficient and focused, with smarter workflows, credential-aware distribution, live SLA dashboards and personalized worklists.

    RUBEE® AI – Embedded intelligence that supports clinical control

    Flexible and vendor-neutral, RUBEE® AI provides seamless access to curated and third-party algorithms, with AI results integrated directly into the diagnostic workflow. It is deeply embedded to deliver fast decision support that enhances rather than replaces human expertise, enabling radiologists to work with greater efficiency, consistency and confidence.

    Enterprise Imaging Cloud – Seamless imaging, with no barriers

    Delivering imaging without barriers, Enterprise Imaging Cloud is a fully managed SaaS solution that removes complexity from IT operations, speeds deployment, and guarantees up to 99.99% uptime. With trusted security, effortless scalability, and peace of mind built in, it keeps imaging seamless – everywhere.

    Radiating Rays of Knowledge
    Education stands at the heart of our presence at ECR 2026. Through interactive sessions and expert dialogues, AGFA HealthCare shares insights that empower clinicians – helping them grow, connect, and evolve together.

    AI Lightning Talk: “From Pixels to Practical Outcomes: Orchestrating Trustworthy AI Across Radiology with Enterprise Imaging” – Weds 4 March 14:10 – 14:30

    See ground-breaking Augmented Intelligence at the AI Lightning Talk! Taking place in the AI Theatre, Dr Anjum Ahmed, Global Chief Medical Officer and Global Director Enterprise Imaging & AI, will deliver an outstanding session on Workflow Intelligence, Foundation Models, and the Art of Clinical Trust in the AI Era.

    Clinical Lunch & Learn Session: “Networked Radiology and AI for a Sustainable Imaging Future” – Thursday 5 March 13:00

    Engage with our panel of European Radiologists at the Satellite Symposium session, taking place in Room G2 (Level -2). Dr Peter Strouhal (Alliance Medical – UK), plus Dr Davide Ippolito (Fondazione IRCCS San Gerardo dei Tintori, Italy), Dr Filip Deckers (ZAS Hospital, Belgium), and Dr Athanasios Chalazonitis (Alexandra General Hospital, Greece) form an incredible team of imaging disrupters. They will be discussing discuss how Imaging Health Networks and AI-enabled workflows are transforming radiology services.

    We cannot wait to see you in Vienna. Join #TeamAGFA as we stand proud on our Empowerer pedestal, shaping our own legacy by placing the ‘Clinician-First’. And when Clinicians are first, we see imaging empowered. That’s life in flow.

    See the future of imaging at ECR 2026. Booth #X2 214. To schedule a demo or register for clinical sessions, visit: www.agfahealthcare.com/ecr

    About AGFA HealthCare
    At AGFA HealthCare, we understand that striking the critical balance between clinical efficiency and quality patient care starts with the clinician experience. We recognize how vital it is for clinicians to be fully immersed in their cases, channeling all their energy into delivering confident, informed diagnoses. That’s why we designed our Enterprise Imaging platform to eliminate the barriers that get in the way. When distractions melt away, technology feels like an extension of one’s thought process, and each clinician has everything they need to perform at the top of their craft. That’s life in flow.

    This belief shapes everything we do – guided by our Mission, Vision, and Customer Delivery Principles, which are designed to empower clinicians and elevate their experience.

    AGFA HealthCare is a division of the Agfa-Gevaert Group. For more information on AGFA HealthCare, please visit www.agfahealthcare.com and follow us on LinkedIn.

    AGFA and the Agfa rhombus are registered trademarks of Agfa-Gevaert N.V. Belgium or its affiliates. All information contained herein is intended for guidance purposes only, and the characteristics of the products and services described in this publication can be changed at any time without notice. Products and services may not be available for your local area. Please contact your local sales representative for availability information. AGFA HealthCare diligently strives to provide as accurate information as possible but shall not be responsible for any typographical error.

    Media Contact

    Jessica Baldry, Global Marketing & Communications, jessica.baldry@agfa.com Tel +44 7583 203971

    SOURCE: Agfa HealthCare

  • OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC

    Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine

    OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC.

    Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receive royalties based on a tiered percentage of annual net sales. While the detailed financial terms are not disclosed in accordance with the confidentiality provisions, the overall deal economics are broadly comparable to those of recent similar licensing transactions in the market.

    TegMine will obtain the exclusive global rights to develop and commercialize the ADC under the license agreement. This international licensing collaboration reflects the potential value of products generated using OBI’s Obrion™ ADC technologies.

    The licensed ADC candidate is derived from a high-affinity anti-glycan antibody provided by TegMine and was developed into an ADC by OBI using the Obrion™ ADC technology family, including the GlycOBI® glycan-conjugation technology, the dual-function enzymatic EndoSymeOBI®, and the highly hydrophilic linker HYPrOBI®. The ADC candidate generated with this proprietary site-specific glycan conjugation is homogeneous and scalable for manufacturing.

    Heidi Wang, Ph.D. Chief Executive Officer of OBI Pharma, said, “This strategic collaboration leverages the complementary strengths of both organizations. It not only supports the advancement of OBI’s ADC product development but also expands opportunities for strategic partnerships using our innovative ADC technologies such as GlycOBI®. We look forward to working closely with TegMine to further develop this novel ADC that may benefit patients with urgent medical needs.”

    “The transition from our successful Master Services Agreement to this global license agreement is a major milestone for TegMine,” said Jeff Bernstein, Ph.D., Chief Executive Officer of TegMine Therapeutics. “By combining OBI’s site-specific GlycOBI® conjugation with our proprietary antibodies discovered via the TegMiner™ platform, we have generated an ADC with exceptional tumor specificity. This TegMine program demonstrates the power of targeting cancer-specific glycan signatures to deliver potent payloads while sparing healthy tissue. We are excited to advance this program rapidly into the clinic.”

    About GlycOBI®
    OBI has developed a unique glycan-based ADC technology (GlycOBI®), designed in a Plug and Play format that is compatible with any antibodies, linkers, and payloads, and supports various drug-antibody ratios (DAR). Powered by OBI’s proprietary dual-function enzymatic technology EndoSymeOBI® and its hydrophilic linker technology HYPrOBI®, GlycOBI®, a core component of OBI’s Obrion™ ADC technology family, enables the generation of site-specific and homogeneous ADCs with an efficient and scalable process under GMP conditions.

    During the conjugation process, GlycOBI® avoids disrupting the antibody structure and ensures that the resulting ADC retains biophysical characteristics comparable to the native antibody. In addition, OBI’s linker technology improves payload conjugation efficiency and reduces the propensity for aggregation or degradation, further supporting a stable and well-controlled ADC manufacturing process. GlycOBI® has overcome limitations commonly associated with traditional ADC approaches and has demonstrated improved antitumor activity and stability in various in vivo studies.

    About OBI Pharma
    OBI Pharma is a clinical-stage global oncology company established in 2002 and headquartered in Taiwan. Together with its subsidiary OBI Pharma USA, Inc., the company is dedicated to developing innovative cancer therapeutics to provide new treatment options for patients with urgent medical needs.

    OBI’s research efforts center on novel antibody-drug conjugates (ADC). Through its patented next-generation conjugation technology platform, Obrion™, OBI has established diverse ADC design modalities. The platform integrates proprietary conjugation and linker technologies, including GlycOBI®, GlycOBI DUO®, EndoSymeOBI®, HYPrOBI®, and the novel cysteine-conjugation technology ThiOBI®, to advance next-generation ADC solutions. OBI has developed a next-generation suite of ADC programs. These include monospecific ADCs such as OBI-902 (TROP2) and OBI-904 (Nectin-4); a bispecific single-payload ADC, OBI-201 (HER2 x TROP2); and a bispecific dual-payload ADC, OBI-221 (cMET x HER3). In addition to its ADC programs, OBI’s assets include OBI-3424, a first-in-class AKR1C3-targeted small-molecule prodrug that selectively releases a potent DNA-alkylating agent in the presence of the aldo-keto reductase 1C3 enzyme, which is highly expressed in certain tumors. Additional information can be found at www.obipharma.com.

    GlycOBI®, EndoSymeOBI®, ThiOBI®, HYPrOBI®, and GlycOBI DUO® are registered trademarks of OBI. Obrion™ is a trademark under registration.

    About TegMine Therapeutics
    TegMine is redefining precision oncology by targeting highly expressed glycans and glycoproteins that drive cancer aggressiveness and immune evasion. Our mission is to eradicate cancer by identifying unique tumor antigens that are consistently prevalent across the tumor while being largely absent from healthy tissues. The company’s proprietary TegMiner™ platform utilizes glyco-engineered cell lines and advanced mass spectrometry to identify previously inaccessible, cancer-specific glycan epitopes. This discovery engine is designed to generate high-specificity antibodies that deliver maximum therapeutic impact across numerous treatment modalities, including antibody-drug conjugates (ADCs) and other next-generation antibody formats. For more information, please visit www.tegminetx.com.

    Forward-Looking Statements
    Statements included in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about future clinical trials, results and the timing of such trials and results. Such risk factors are identified and discussed from time to time in OBI Pharma’s reports and presentations, including OBI Pharma’s filings with the Taiwan Securities and Futures Bureau.

    COMPANY CONTACT:
    Kevin Poulos, Chief Business Officer
    OBI Pharma USA, Inc.
    +1 (619) 537 7698, ext. 102
    kpoulos@obipharma.com

    Jeff Bernstein, Chief Executive Officer
    TegMine Therapeutics, Inc.
    jeff@tegminetx.com

    SOURCE: OBI Pharma USA, Inc.

  • PromiCell, Inc. presents during JP Morgan’s 2026 Healthcare Conference

    PromiCell, Inc. (the Company), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company’s Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company’s lead asset PRO CAR – 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level).

    About PromiCell, Inc.
    PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 TCR T cells and CD 33 CAR T cells, applicable for the treatment of patients with mCRPC, Ewing Sarcoma, recurrent leukemia and acute myeloid leukemia. Our next-generation chimeric antigen receptor CAR T cell therapies are designed to address key mechanisms of tumor escape, disease relapse, and immune evasion. Our scientists are pioneers in CAR T-cell therapy, united in a mission to outsmart cancer and deliver more cures for patients. Learn more at www.promicell.com.

    Contact:
    305-433-1287
    anthony@promicell.com

    SOURCE: Promicell

  • Fullerton Health Deepens Specialty Care Capabilities Through Acquisition of Singapore-Based Otolaryngology Practice, The ENT Clinic

    Fullerton Health Deepens Specialty Care Capabilities Through Acquisition of Singapore-Based Otolaryngology Practice, The ENT Clinic

    Leading regional private healthcare provider group Fullerton Health (“Fullerton Health” or the “Group”) said today it has successfully acquired one of Singapore’s largest otolaryngology (Ear, Nose, & Throat – “ENT”) specialist practices, The ENT Clinic Pte Ltd (“The ENT Clinic”), to deepen its specialty care capabilities in its home market as part of its growth strategy.

    The ENT Clinic’s team of specialists: (L-R): Dr Jeeve Kanagalingam, Dr Chris Hobbs, Dr Ho Eu Chin, Dr Rebecca Heywood, Dr Sandeep Uppal

    Founded by experienced ENT specialist Dr Jeeve Kanagalingam in 2015, the ENT Clinic has grown from a single doctor practice to a network of five specialists operating across three clinics which are well-placed in Singapore’s medical hubs, Camden, Novena and Gleneagles Tanglin. These specialists cover various crucial sub-specialties of ENT and have a strong reputation for clinical excellence.

    This acquisition will enable Fullerton Health to strengthen its presence in the ENT space, which has been identified as one of the top specialties focus for the Group given the high referral volumes and synergy within the Group’s services, which include diagnostic imaging, executive health screening, primary care, and network management referral.

    The acquisition will expand Fullerton Health’s network of high-quality specialist care and allow the Group to better deliver integrated, patient-centric healthcare services across Southeast Asia. Fullerton Health’s other specialist care capabilities in Singapore include cardiology, orthopaedics, and endocrinology, amongst others.

    “We are delighted to welcome The ENT Clinic into the Fullerton Health family,” said Ms Margareta Laminto, Managing Director, Specialist & RadLink, and Group Chief Sustainability Officer of Fullerton Health. “Acquiring a market leader with strong brand perception in Singapore’s ENT clinical services not only expands our clinical service capabilities but also enables us to tap into new opportunities and serve more patients with quality coordinated care. This enhances our ability to deliver seamless, accessible, and trusted care to our members, patients and customers.”

    Following the acquisition, The ENT Clinic will be able to access the Group’s ecosystem of coordinated medical care, enabling seamless multidisciplinary collaboration and enhanced care for Fullerton Health’s patient base of over 4.5 million covered lives across the region.

    Fullerton Health’s Specialist Division will collaborate closely with the ENT specialists to unlock new growth opportunities and deliver integrated ENT care to patients across Fullerton Health’s extensive regional network.

    The ENT Clinic’s team will continue to operate under its current brand name, ensuring continuity of care and preserving the trusted relationships it has built with patients and referring physicians. Supported by Fullerton Health’s operational expertise and network, the clinic will also explore opportunities to expand service offerings, invest in technology, and strengthen clinical service initiatives in ENT care.

    “Joining Fullerton Health marks an exciting new chapter for The ENT Clinic,” said Dr Jeeve Kanagalingam, Founder, The ENT Clinic. “We see strong synergies in partnering with a well-established healthcare organisation with deep operational and clinical expertise. Fullerton Health’s long-term commitment to building sustainable healthcare platforms aligns closely with our values. Together, we can enhance access to quality ENT care while preserving the high standards and patient-centric ethos our clinic is known for.”

    About Fullerton Health

    Fullerton Health is a leading integrated healthcare solutions provider. Established in 2010, the Group operates across the Asia-Pacific region, with close to 550 clinics and a network of over 18,000 providers. It supports the entire care journey – from managed care and network management to primary care, diagnostics, specialty, and ancillary services.

    Fullerton Health combines clinical excellence with tailored corporate healthcare programs, medical advisory expertise, and digital innovation to meet the diverse needs of its clients. Guided by its purpose – seamless, accessible and trusted healthcare for all – the Group is committed to delivering high-quality care across the region. https://www.fullertonhealth.com

    Fullerton Health Media Contact:

    Veronica Chiu
    Senior Vice President,
    Group Corporate Communications & Singapore Marketing
    Fullerton Health
    Email Address: comms@fullertonhealth.com

    About The ENT Clinic

    Founded in 2015, The ENT Clinic is located at Mt Elizabeth Novena Hospital, Gleneagles Hospital and Camden Medical Centre in Singapore. Its specialists in Otolaryngology, Head and Neck Surgery and Facial Plastic Surgery, with combined training and work experience of over 100+ years in the United Kingdom, Australia, Canada, India and Singapore, are supported by experienced nurses, speech therapists and audiologists. https://www.entclinic.sg